Axar.az
UP

Pfizer shows long-term efficacy in adolescents

Home page Health
12 Punto 14 Punto 16 Punto 18 Punto

Pfizer Inc (PFE.N) said on Monday its COVID-19 vaccine provided strong long-term protection against the virus in a late-stage study conducted among adolescents aged 12 to 15 years.

Axar.az reports that two-dose series of the vaccine was 100% effective against COVID-19, measured seven days through over four months after the second dose, the company said.

A syringe is filled with a dose of Pfizer's COVID-19 vaccine at a pop-up community vaccination center at the Gateway World Christian Center in Valley Stream, New York, U.S., February 23, 2021.

The long-term data will support planned submissions for full-regulatory approval of the vaccine in the age group in the United States and worldwide.

Pfizer and BioNTech will seek clearance for a 30 micrograms dose of the vaccine for those aged 12 and above.

Date
2021.11.22 / 22:32
Author
Axar.az
Comments
See also

Iran records 79 coronavirus-related deaths

Georgia confirms another 59 COVID-19 deaths

Iran records 77 coronavirus-related deaths

Armenia’s coronavirus death toll nears 7,700

Azerbaijan confirms 1,394 more COVID-19 cases

Russia detects 32,602 daily COVID-19 cases

Georgia's COVID tally exceeds 865,000

Don't panic about Omicron variant, WHO says

Omicron hazard for children: increased infection

Georgia records 67 coronavirus death cases

Xocalı soyqırımı — 1992-ci il Bağla
Bize yazin Bağla
ArxivBağla